Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Apr 18;5(2):244-245.
doi: 10.1016/j.jaccao.2023.03.005. eCollection 2023 Apr.

Bridging the Knowledge Gap for Older Patients With CLL on Ibrutinib

Shazia Nakhoda  1   2 , Eman Hamad  2
Affiliations
Editorial

Bridging the Knowledge Gap for Older Patients With CLL on Ibrutinib

Shazia Nakhoda et al. JACC CardioOncol. .
No abstract available

Keywords: BTK inhibitor; atrial fibrillation; chronic lymphocytic leukemia; hemorrhage; ibrutinib.

PubMed Disclaimer

Conflict of interest statement

Dr Nakhoda has served on the advisory board for Bristol Myers Squibb. Dr Hamad has reported that she has no relationships relevant to the contents of this paper to disclose.

Figures

None
Graphical abstract
See this image and copyright information in PMC

Comment on

  • doi: 10.1016/j.jaccao.2023.02.001

References

    1. Shanafelt T.D., Wang X.V., Hanson C.A., et al. Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood. 2022;140(2):112–120. - PMC - PubMed
    1. Brown J.R., Hillmen P., O’Brien S., et al. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia. 2018;32(1):83–91. - PMC - PubMed
    1. Byrd J.C., Hillmen P., Ghia P., et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39(31):3441–3452. - PMC - PubMed
    1. Brown J.R., Eichhorst B., Hillmen P., et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2022;388(4):319–332. - PubMed
    1. Byrd J.C., Brown J.R., O’Brien S., et al. Ibrutinib versus of atumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–223. - PMC - PubMed

Publication types

LinkOut - more resources